Navigation Links
CryoLife Announces First Implant of Combination Aortic-Mitral Allograft Heart Valve at the Cleveland Clinic
Date:5/12/2008

ATLANTA, May 12 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY), a biomaterials, medical device and tissue processing company, today announced the first implantation of the combination aortic-mitral allograft heart valve in a patient at the Cleveland Clinic. The surgery was performed by Dr. Jose Navia, a cardiac surgeon with the Heart and Vascular Institute at the Cleveland Clinic.

The method used to process the combination aortic-mitral human heart valve was developed by CryoLife in collaboration with the Cleveland Clinic. The innovative valve was developed as a replacement option for patients with infective endocarditis involving both the aortic and mitral valves. Infective endocarditis is a condition in which the structures of the heart, particularly the heart valves, are infected.

"Infections involving both the mitral and aortic valves put patients at very high risk for serious complications that can result in death," said Dr. Navia. "With the new human tissue combination aortic-mitral heart valve, we are hoping to provide an infection-resistant treatment option to offer patients."

Dr. Navia developed the concept for the aortic and mitral valve replacement option and is a paid consultant for CryoLife.

"It was very exciting to work closely with the Cleveland Clinic on this breakthrough development in cardiac reconstruction procedures," said Steven G. Anderson, president and CEO of CryoLife. "At CryoLife, we are dedicated to advancing technology for the treatment of patients suffering from complex cardiac disease. The new aortic-mitral allograft heart valve is a wonderful new option for patients suffering from infective endocarditis."

About Infective Endocarditis

Infective endocarditis is a
'/>"/>

SOURCE CryoLife, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Nventa Announces Additional Positive Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial
2. Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results
3. Cytopia Announces Novel Anti-Cancer Drug Development Collaboration
4. Vion Pharmaceuticals Announces Initiation of Clinical Trial of Cloretazine(R) (VNP40101M) in Combination with Cytarabine
5. Trubion Announces Initiation of Phase 2b Study of TRU-015 for the Treatment of Rheumatoid Arthritis
6. Arena Pharmaceuticals, Inc. Announces Initiation of Phase 1 Clinical Trial of Drug Candidate Under Partnership with Taisho Pharmaceutical Co., Ltd.
7. XTENT Announces Clinical Trial Data to be Presented at Annual EuroPCR Meeting Next Week
8. Exelixis Announces First Quarter 2008 Financial Results
9. PEAK Surgical Announces Positive Results From Preclinical Study of PEAK PlasmaBlade(TM) for Obstetric and Gynecologic Surgery
10. N30 Pharma Announces Completion of Phase 1 Clinical Studies With N30-201
11. Senetek PLC Announces Positive Results from Pyratine-6(TM) Clinical Trial in Patients with Acne Rosacea
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... 30, 2014  Alimera Sciences, Inc. (NASDAQ: ... the research, development and commercialization of prescription ophthalmic pharmaceuticals, ... advance from Hercules Technology Growth Capital, Inc. (NYSE: ... and final advance under the Loan and Security Agreement ... , Alimera Sciences Limited, entered into with Hercules ...
(Date:9/30/2014)... , Sept. 30, 2014 A study ... (OCT), offered a new look at the composition of ... how physicians understand and treat the disease, a leading ... at Baptist Health Lexington between September 2010 and May ... the Journal of the American College of Cardiology ...
(Date:9/30/2014)... Quebec , Sept. 30, 2014 Valeant ... TSX: VRX) today announced that the company,s ... Letter from the U.S. Food and Drug Administration (FDA) ... Company,s records with regards to Sculptra Aesthetic injectable, which ... Warning Letter pertains to the management of Valeant,s contract manufacturers ...
Breaking Medicine Technology:Alimera Sciences Receives $25 Million Advance from Hercules Technology Growth Capital 2New Imaging Tool May Allow Tailoring of Stroke Prevention to Each Patient 2Valeant Pharmaceuticals' Bridgewater Location Receives Warning Letter From FDA 2
... Jan. 31, 2012 Halozyme Therapeutics, Inc. (NASDAQ: ... Phase 1 proof-of-concept and local tolerability study of HTI-501 ... 8th World Congress of the International Academy of Cosmetic ... commencement of the Phase 2 portion of the clinical ...
... LAKES, N.J., Jan. 31, 2012 The Board of Directors of ... declared a quarterly dividend of 45 cents per common share, payable ... 2012. The indicated annual dividend rate is $1.80 per share. ... is a leading global medical technology company that develops, manufactures and ...
Cached Medicine Technology:HTI-501 Data Support Commencement of Phase 2 Portion of Clinical Trial 2HTI-501 Data Support Commencement of Phase 2 Portion of Clinical Trial 3
(Date:9/30/2014)... the spiraling costs of drugs paid for by the ... meaningful impact on cancer chemotherapy drug costs, say a ... Oncology published online today. , "We looked at ... cancers, and did not find a substantial change in ... the recent Medicare law in 2005," says the study,s ...
(Date:9/30/2014)... Centers (FQHCs) granted new patient appointments to Medicaid ... other primary care practices (non-FQHCs), in addition to ... a new 10-state University of Pennsylvania study published ... Using data from a previous "secret shopper" study ... that FQHCs community health clinics that receive ...
(Date:9/30/2014)... 2014 Glycodrive , one of ... to help maximize lean, strong muscle growth with a ... of glucose has caught the attention of Shane Michaels, ... behind Glycodrive is to help the body use carbohydrates ... “Carbs are essential in the muscle-building process, and Glycodrive ...
(Date:9/30/2014)... 30, 2014 The American Diabetes ... help diabetics curb their sweet tooth, but the most ... this September, suggests that zero-calorie sweeteners may actually be ... , The Weizmann Institute of Science in Israel ... sweeteners to mice, the mice developed glucose intolerance. They ...
(Date:9/30/2014)... September 30, 2014 With the ... strains emerging every day, it’s a perfect time ... The EnviroShield system is an electro-static disinfectant delivery ... to surface normally missed with spray-on disinfectant applicators. ... that adds an electrostatic negative charge to the ...
Breaking Medicine News(10 mins):Health News:Landmark Medicare law had little impact on reducing chemotherapy cost 2Health News:Medicaid and Uninsured patients obtain new patient appointments most easily at FQHCs 2Health News:Glycodrive Review Exposes Blue Star Nutraceutical’s Supplement for Leaner, Stronger Muscles 2Health News:Artificial Sweeteners May be Linked to Greater Diabetes Risk 2Health News:Columbus Janitorial Company Announces New Disinfecting System for your workplace 2
... (NEWARK, N.J., March 18, 2008) Julia Duane Quinlan, ... remove her daughter from a respirator changed the use ... annual Joe and Julia Quinlan Award to Dr. John ... Rev. Charles J. Hudson and Margaret J. Coloney from ...
... than 30% Enrolled in Consumer-Driven Plans Have Household ... Enrollment in,consumer-driven and high-deductible health plans increased ... of the overall insurance market, according,to the third ... Enrollment in consumer-driven plans with a tax-advantaged,account was ...
... Inc. (NYSE: BRL ), today confirmed that ... Deutsche Bank, acting as PLIVA,s GDR,Depositary, on termination ... June 19, 2008 ("Termination Date"). Once the Deposit,Agreement ... from the London,Stock Exchange ("LSE"), a process that ...
... Internal Controls and Procedures Improvements, Corporate, Governance Enhancements, ... Va., March 18 Sunrise Senior Living,Inc. (NYSE: ... New York Stock,Exchange ("NYSE") that the Company did not ... filing its 2006 Form 10-K. The Company also,announced the ...
... severe inherited metabolic disorder, which is associated with ... cardiac manifestations in Wilson,s disease include arrhythmias and ... Ihtisas Hospital and in Ankara University Faculty of ... non-invasive marker of intra-atrial conduction disturbance in patients ...
... who experience military combat obviously endure extreme stress, and ... of post-traumatic stress disorder, or PTSD. PTSD is ... However, as researcher Roger Pitman explains, Although it ... by the traumatic event, it is also possible that ...
Cached Medicine News:Health News:Julia Quinlan to present awards at a conference hosted by Rutgers College of Nursing 2Health News:New EBRI/Commonwealth Fund Research: Enrollment in Consumer-Driven Plans Remains Low, Survey Shows 2Health News:New EBRI/Commonwealth Fund Research: Enrollment in Consumer-Driven Plans Remains Low, Survey Shows 3Health News:New EBRI/Commonwealth Fund Research: Enrollment in Consumer-Driven Plans Remains Low, Survey Shows 4Health News:Barr's PLIVA Subsidiary to Terminate GDR Deposit Agreement and Delist From London Stock Exchange 2Health News:Barr's PLIVA Subsidiary to Terminate GDR Deposit Agreement and Delist From London Stock Exchange 3Health News:Barr's PLIVA Subsidiary to Terminate GDR Deposit Agreement and Delist From London Stock Exchange 4Health News:Sunrise Misses NYSE Deadline for Filing 2006 Form 10-K 2Health News:Sunrise Misses NYSE Deadline for Filing 2006 Form 10-K 3Health News:Sunrise Misses NYSE Deadline for Filing 2006 Form 10-K 4Health News:Sunrise Misses NYSE Deadline for Filing 2006 Form 10-K 5Health News:Sunrise Misses NYSE Deadline for Filing 2006 Form 10-K 6Health News:Sunrise Misses NYSE Deadline for Filing 2006 Form 10-K 7Health News:Sunrise Misses NYSE Deadline for Filing 2006 Form 10-K 8Health News:Sunrise Misses NYSE Deadline for Filing 2006 Form 10-K 9Health News:How does P wave dispersion change in patients with Wilson's disease? 2Health News:Does stress damage the brain? 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: